Skip to main content
Midas Edge

NEUROCRINE BIOSCIENCES INC

For the period ended Sep 30, 2026. Filed Nov 2, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 2, 2026

NBIX$168.86+2.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 5. Other Information

During the period from July 1, 2026 to September 30, 2026, our officers (as defined in Rule 16a-1(f) under the Exchange Act) and/or directors adopted orterminated contracts, instructions or written plans for the purchase or sale of our securities as noted below:

Name and TitleActionDateTrading ArrangementTotal Shares Authorized to be Sold***Expiration Date
Rule 10b5-1* · Non-Rule 10b5-1**
William RastetterAdoption9/3/2026X18,0005/22/2027
Director
Julie CookeAdoption8/31/2026X15,6863/31/2027
Chief Human Resource Officer
Richard PopsAdoption8/27/2026X15,0005/21/2027
Director
Gary LyonsAdoption8/18/2026X15,0005/22/2027
Director
David BoyerAdoption8/11/2026X4,5125/18/2028
Chief Corporate Affairs Officer
Sanjay KeswaniAdoption8/7/2026X11,2001/30/2027
Chief Medical Officer (through Sep. 25, 2026)
  • Intended to satisfy the affirmative defense of Rule 10b5-1(c)

** Not intended to satisfy the affirmative defense of Rule 10b5-1(c)

*** Represents the maximum number of shares that may be sold pursuant to the 10b5-1 arrangement. The number of shares sold is dependent on the satisfaction of certain conditions as set forth in the written plan and the satisfaction of applicable vesting conditions of equity awards.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.